Now we actually have a cause to do away with Kim Jong-un. South Korea simply retains on including groundbreaking firms engaged on hair loss remedies. See my web page on hair loss analysis around the globe for a number of the foremost names. My newest three weblog posts all cowl new groundbreaking work from South Korea. Actually outstanding and completely unintentional.
CosmeRNA from Sirnagen Releasing in 2023
This submit covers a brand new topical hair loss product referred to as CosmeRNA, whose web site is now reside. It’s made by siRNAgen (South Korea), a subsidiary of Bioneer (South Korea). I briefly lined this firm up to now, however now it deserves its personal submit.
The rationale I’m scripting this submit is because of an excellent new interview with siRNAgen CEO Dr. June Park. Each these new developments had been despatched to me by a reader who needs to stay nameless. Key quote from Dr. Park (additionally see her Linkedin):
“The primary SAMiRNA product might be accessible on the market within the first half of 2023. We had an unconventional path to commercialization by creating a hair loss cosmeceutical product. CosmeRNA, named after beauty RNA, offered an early validation of our platform’s potential as a topical beauty product for androgenetic alopecia (hair loss).”
They wil not have to conduct scientific trials since it is a beauty product! The precise launch date is more likely to be in early 2023 per one other quote in the identical interview. After first being completed in South Korea, CosmeRNA’s security examine was repeated in Europe by Dermatest in 2022. Be aware that SAMiRNA is shelf secure in an answer for a yr, so it may be utilized topically.
Ms. Park anticipates the product launch to happen a while in early 2023. They may deal with the European market first as a result of area’s extra streamlined cosmeceutical trial and approval course of. It’s referred to as Cosmetics Product Notification Portal (CPNP).
Be aware that I beforehand briefly lined siRNAgen Therapeutics in my submit on OliX Prescription drugs. The latter is engaged on a hair loss treatment involving RNA interference (RNAi) by way of asiRNA (uneven small interfering RNA). The intention is to scale back androgen receptor (AR) expression on the scalp.
SAMiRNA, Androgen Receptor and Hair Development
siRNAgen can be engaged on decreasing AR expression and regrowing hair. Nevertheless, it’s doing so by way of remedy with self-assembled micelle inhibitory RNA (SAMiRNA) nanoparticle-type siRNA. See their web site for extra on small interfering RNAs (siRNA).
They printed an necessary examine on this in Nature Journal in January 2022. The encouraging title of this paper is price posting: “Weekly remedy with SAMiRNA concentrating on the androgen receptor ameliorates androgenetic alopecia.”
The product they use for androgenetic alopecia is a topical referred to as AR68. It’s categorized as a beauty ingredient and might be referred to as Cosmerna-68. Within the above talked about paper, they’ve earlier than and after pictures of a affected person that I pasted beneath. The chart on the precise exhibits the precise % enchancment with AR68 0.5mg/ml remedy versus placebo. Additionally they state the next:
“Within the low-dose (0.5 mg/ml) scientific examine, AR68 was utilized 3 times per week for twenty-four weeks, and thru quantitative evaluation utilizing a phototrichogram, we confirmed will increase in complete hair counts. Within the 24-week lengthy high-dose (5 mg/ml) scientific examine, AR68 confirmed common extra hair progress of 1.3-1.9 hairs/cm2 monthly, which is akin to finasteride. No unintended effects had been noticed. Due to this fact, SAMiRNA concentrating on AR mRNA is a possible novel topical remedy for AGA.”
Edit: The upper dose AR68 5mg/ml earlier than and after pictures are right here.
Is that this a miracle? Probably not for many severaly balding individuals individuals. Nevertheless, simply as with finasteride, some individuals may see stellar outcomes. And for individuals who are simply beginning to go bald, this may very well be a a lot wanted non-DHT inhibiting product with few if any unintended effects.
I’m not an enormous believer in cosmetics, however this newest interview with siRNAgen CEO June Park is encouraging. She comes throughout as very clever and honest.
